首页> 外国专利> Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications

Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications

机译:基于指数模式识别的细胞靶向组合物,方法和抗癌应用

摘要

The present invention relates to the compositions, methods, and applications of a new approach to pattern recognition based targeting by which an exponential amplification of effector response can be specifically obtained at a targeted cells. The purpose of this invention is to enable the selective delivery of large quantities of an array of effector molecules to target cells for diagnostic or therapeutic purposes. The invention is comprised of two components designated as “Compound 1” and “Compound 2”: Compound 1 is comprised of a cell binding agent and a masked female adaptor. Compound 2 is comprised of a male ligand, an effector agent, and two or more masked female receptors. The male ligand is selected to bind with high affinity to the female adaptor. Compound 1 can bind with high affinity to the target cell and the female receptor can then be unmasked by an enzyme enriched at the tumor cell. The male ligand of Compound 2 can then bind to the unmasked female adaptor bound to the target cell. The masked female adaptor on the bound Compound 2 can then be specifically unmasked. One receptor has in effect become two. Two new molecules of Compound 2 can bind to the unmasked adaptors receptors. After unmasking two receptors in effect become four. The process can continue in an explosive exponential like fashion resulting in enormous amplification of the number of effector molecules specifically deposited at the target cell.
机译:本发明涉及基于模式识别的靶向的新方法的组合物,方法和应用,通过该方法可以在靶细胞上特异性获得效应子反应的指数扩增。本发明的目的是为了诊断或治疗目的,能够选择性地将大量效应分子阵列选择性地递送至靶细胞。本发明由称为“化合物1”和“化合物2”的两个组分组成:化合物1由细胞结合剂和被掩盖的雌性衔接子组成。化合物2由雄性配体,效应剂和两个或多个被掩蔽的雌性受体组成。选择雄配体以高亲和力结合雌配体。化合物1可以高亲和力与靶细胞结合,然后雌性受体可以被肿瘤细胞富集的酶所掩盖。然后,化合物2的雄性配体可以与结合至靶细胞的未掩盖的雌性配体结合。然后可以对结合的化合物2上的被掩盖的母接头进行特定的去掩盖。一个受体实际上变成了两个。化合物2的两个新分子可以与未掩盖的衔接子受体结合。揭露后,两个受体实际上变成了四个。该过程可以以爆炸性指数状的方式继续进行,从而导致特异性沉积在靶细胞上的效应分子数量的极大扩增。

著录项

  • 公开/公告号US2007172422A1

    专利类型

  • 公开/公告日2007-07-26

    原文格式PDF

  • 申请/专利权人 ARNOLD GLAZIER;

    申请/专利号US20060593938

  • 发明设计人 ARNOLD GLAZIER;

    申请日2006-11-07

  • 分类号A61K51/00;A61K38/16;C07K14/00;C07K9/00;

  • 国家 US

  • 入库时间 2022-08-21 21:05:44

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号